Results 71 to 80 of about 54,207 (313)

Dasatinib-Induced CMV Hepatitis in an Immunocompetent Patient: A Rare Complication of a Common Drug

Translational Oncology, 2016
Dasatinib is a common anticancer drug used in the treatment of leukemia. Several side effects have been reported, the most common being myelosuppression, diarrhea, edema, and nausea.
Fidencio Davalos, Benjamin Chaucer, Wahib Zafar, Shamim Salman, Jay Nfonoyim   +4 more
doaj   +1 more source

A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.

Neuro-Oncology, 2021
BACKGROUND Glioblastoma is the most common primary malignancy of the central nervous system with dismal prognosis. Genomic signatures classify isocitrate dehydrogenase 1 (IDH)-wildtype glioblastoma into three subtypes: proneural, mesenchymal and ...
O. Alhalabi, M. Fletcher, T. Hielscher, T. Kessler, T. Lokumcu, U. Baumgartner, E. Wittmann, S. Schlue, Mona Göttmann, S. Rahman, L. Hai, L. Hansen-Palmus, Laura Puccio, I. Nakano, C. Herold‐Mende, B. Day, W. Wick, F. Sahm, Emma Phillips, V. Goidts   +19 more
semanticscholar   +1 more source

Dasatinib und Nilotinib [PDF]

pharma-kritik, 2009
N ...
openaire   +2 more sources

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Experimental Hematology & Oncology, 2012
Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients.
Gadó Klára, Matolcsy András, Csomor Judit, Kicsi Dóra, Bödör Csaba, Domján Gyula   +5 more
doaj   +1 more source

Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life [PDF]

Клиническая онкогематология, 2017
Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving ...
TI Ionova, NB Bulieva, OYu Vinogradova, TA Gritsenko, LK Kozlova, GB Kuchma, EG Lomaia, ER Machyulaitene, TP Nikitina, NV Novitskaya, AYu Rodionova, EI Usacheva, TV Shneider   +12 more
doaj   +1 more source

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Journal for ImmunoTherapy of Cancer, 2021
Background T cell engagers are bispecific antibodies recognizing, with one moiety, the CD3ε chain of the T cell receptor and, with the other moiety, specific tumor surface antigens. Crosslinking of CD3 upon simultaneous binding to tumor antigens triggers
G. Leclercq, H. Haegel, A. Schneider, A. Giusti, Estelle Marrer-Berger, C. Boetsch, A. Walz, V. Pulko, J. Sam, John Challier, C. Ferlini, A. Odermatt, P. Umaña, M. Bacac, C. Klein   +14 more
semanticscholar   +1 more source

Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease- and drug-dependent dynamic regulation of cell-cell junctions in live tissue [PDF]

, 2015
E-cadherin-mediated cell-cell junctions play a prominent role in maintaining the epithelial architecture. The disruption or deregulation of these adhesions in cancer can lead to the collapse of tumor epithelia that precedes invasion and subsequent ...
Anderson, Kurt I., Campbell, Andrew D., Conway, James R.W., Croucher, David R., Erami Rud Majani, Zahra, Evans, T.R. Jeffry, Gallego-Ortega, David, Grey, Shane T., Gunning, Peter W., Hardeman, Edna C., Herrmann, David, Herzog, Herbert, Kadir, Shereen, Karim, Saadia A., Law, Andrew M., Leung, Wilfred, Lucas, Morghan C., Magenau, Astrid, McGhee, Ewan J., Morton, Jennifer P., Mrowinska, Agata, Murphy, Kendelle J., Nobis, Max, Ormandy, Christopher J., Reischmann, Nadine, Ridgway, Rachel A., Sansom, Owen J., Schwarz, Juliane P., Strathdee, Douglas, Timpson, Paul, Vennin, Claire, Walters, Stacey N., Warren, Sean C., Zhang, Lei   +33 more
core   +2 more sources

Dasatinib as a treatment for Duchenne muscular dystrophy [PDF]

Human Molecular Genetics, 2015
Identification of a systemically acting and universal small molecule therapy for Duchenne muscular dystrophy would be an enormous advance for this condition. Based on evidence gained from studies on mouse genetic models, we have identified tyrosine phosphorylation and degradation of β-dystroglycan as a key event in the aetiology of Duchenne muscular ...
Tracy Emmerson, Leanne Lipscomb, Steve J. Winder, Robert W. Piggott   +3 more
openaire   +3 more sources

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors [PDF]

, 2014
Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR-ABL which activates a number of signal transduction pathways, including PI3K/AKT signaling and consequently inactivates FOXO transcription factors.
Bhatia, Birkenkamp, Breitling, Bruennert, Brunet, Burgering, Chomel, Chu, Copland, Corbin, Druker, Duy, Essafi, Fernandez de Mattos, Ghaffari, Goldman, Graham, Hamilton, Hurtz, Ito, Jorgensen, Kikuchi, Komatsu, Koschmieder, Mahon, Matsumoto, Miyamoto, Naka, Pellicano, Pellicano, Pellicano, Ross, Ross, Rowley, Sarbassov, Skorski, Tothova, Tothova, Trotman   +38 more
core   +2 more sources

Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics

Frontiers in Pharmacology, 2021
Dasatinib is an oral second-generation tyrosine kinase inhibitor known to be used widely in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).
Shiyu He, Ji-feng Bian, Q. Shao, Ying Zhang, Xu Hao, Xingxian Luo, Yufei Feng, Lin Huang   +7 more
semanticscholar   +1 more source